The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations - Schaper-Gerhardt, Katrin; Gutzmer, Ralf; Angela, Yenny; Zimmer, Lisa; Livingstone, Elisabeth; Schadendorf, Dirk; Hassel, Jessica C.; Weishaupt, Carsten; Remes, Bernhard; Kubat, Linda; Spassova, Ivelina; Becker, Jürgen C. (European journal of cancer, 2024)
Gesehen am 25.03.2025